Skip to main content
Equibles
TELA logo

TELA · TELA Bio, Inc. · Metrics

Track TELA — free

Use TELA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TELA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.80 -0.01 (-1.33%) At close · Nov 2 Q1 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 11, 2026
Market Cap
$36.36M
Shares
44.89M
Volume · Nov 2 165.26K Avg daily vol (3M) 232.52K

TELA metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.80
Market cap
$36.36M

Price action

20 metrics
Price change (1W)
-16.1%
Price change (30D)
-28.9%
Price change (3M)
+11.0%
Price change (6M)
-18.1%
Price change (YTD)
-31.3%
Price change (1Y)
-37.7%
Trailing year
Price change (5Y)
-93.7%
52-week high
$1.41
52-week low
$0.56
Change from 52-week high
-42.5%
Change from 52-week low
+44.7%
Annualized volatility
94.6%
Annualized volatility (3M)
100.4%
Beta
1.0
RSI (14D)
33.5
Price vs SMA 50
-19.6%
Price vs SMA 200
-5.5%
Avg volume (3M)
230,272
Relative volume
1.4
Average dollar volume
$214,021

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
44.89M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 128.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 219.7%
P / book
—
FCF yield
-86.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-113.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.2×
reciprocal yield 82.4%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 35.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
67.8%
Operating margin
-42.6%
Trailing 12 months
Net margin
-51.5%
Gross profit (TTM)
$54.19M
Operating profit (TTM)
−$34.01M
Net income (TTM)
−$41.18M
Trailing 12 months
Diluted EPS (TTM)
$-0.77
FCF margin
-39.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.14

Growth

11 metrics
Revenue growth YoY
-4.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$79.91M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+26.6%
Year over year · more shares
Revenue CAGR (3Y)
+24.7%
Revenue CAGR (5Y)
+34.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-68.9%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$31.62M
Quick ratio
2.4
Interest coverage
-4.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$25.66M
Latest balance sheet
Cash & equivalents
$30.42M
Total assets
$59.74M
Total debt
$56.08M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$31.14M
Capital expenditures (TTM)
$480,000
R&D (TTM)
$9.54M
SG&A (TTM)
—
Stock compensation (TTM)
$3.20M
R&D / revenue
11.9%
Stock compensation / revenue
4.0%

Ownership (13F)

9 metrics
13F filers
45
13F filer change QoQ
+9
Institutional ownership
57.4%
Conviction holders (share of 13F filers)
2.2%
Crowding (high-turnover and private-fund holders)
46.2%
Private-fund adviser ownership
44.5%
Active holders' share change QoQ
-3.8%
Holder tenure
16.4
Price vs estimated holder cost
-77.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.3%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
$186,016
Insider-sentiment score
90 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1561921 CUSIP 872381108 13F (30d) 5 filings 5 filers Visit website Investor relations